Dr. Brufsky on the Disease-Free Survival of Aromatase Inhibitors for Breast Cancer

Adam M. Brufsky, MD
Published: Friday, Jul 14, 2017



Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses the 5 versus 10 year disease-free survival of aromatase inhibitors investigated in the NSAPB B-42 trial.

An important ongoing trial is the NSAPB B-42 trial looking at 5 versus 10 years of aromatase inhibitor therapy. Statistically, there was no difference between the disease-free survival of 5 versus 10 years, explains Brufsky.
 


Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses the 5 versus 10 year disease-free survival of aromatase inhibitors investigated in the NSAPB B-42 trial.

An important ongoing trial is the NSAPB B-42 trial looking at 5 versus 10 years of aromatase inhibitor therapy. Statistically, there was no difference between the disease-free survival of 5 versus 10 years, explains Brufsky.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x